LimmaTech Biologics
Lilly gets FDA approval for severe alopecia areata treatment for paediatric patients
Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes
Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal
The deal focuses on addressing critical unmet medical needs
Lilly to acquire Merida Biosciences in deal worth up to $2.875bn
The acquisition is to advance treatments for serious autoimmune and allergic diseases
Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes
The UK is the first country in Europe to authorise the oral medication
Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer
Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually
Lilly to acquire AtaiBeckley in deal worth $2.8bn
The acquisition will advance therapies for treatment-resistant depression and other mental health conditions
Ipsen to acquire Memo Therapeutics in deal worth more than €700m
The deal expands the company’s rare disease portfolio
Vertex to acquire Crinetics in deal worth around $10bn
The deal includes an approved treatment for acromegaly and other pipeline candidates
Novartis to acquire Myricx Bio in deal worth $1.5bn
Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates
Klick Health acquires Oxford PharmaGenesis
The move expands Klick’s scientific expertise in oncology and rare diseases
Zymeworks to acquire Theravance Biopharma in deal worth $929m
The acquisition will give the company access to a treatment for COPD
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma